Abstract
Glioblastoma remains one of the most aggressive and treatment-resistant brain tumors, largely due to the restrictive nature of the blood-brain barrier (BBB) and the limited bioavailability of systemic therapies. Axitinib, a potent VEGF receptor tyrosine kinase inhibitor, shows therapeutic potential for glioblastoma due to its anti-angiogenic properties. However, its clinical application i…
